United Kingdom Virus Filtration Market

The United Kingdom Virus filtration market size is forecast to grow from approximately USD 680 million in 2025 to around USD 1,750 million by 2035. According to Decision Advisors, a detailed research report on the virus filtration market indicates that the biologics-driven virus filtration consumables trend dominates the market, accounting for approximately 57.4% of the total share in the United Kingdom. BASF SE leads the market with an estimated 24% United Kingdom market share. The company's annual revenue of approximately USD 3.7-4 billion is making it one of the most influential forces shaping industry trends and overall market growth.

Market Snapshot

• United Kingdom Virus filtration market size (2025): USD 680 Million
• Projected United Kingdom Virus filtration market Size (2035): USD 1,750 Million
• United Kingdom Virus filtration market Compound Annual Growth Rate (CAGR): 9.91%
• Base Year: 2025
• Historical Period: 2021-2024
• Forecast Period: 2026-2035

Market Overview/Introduction

The United Kingdom Virus Filtration Market refers to the industry focused on technologies and systems used to remove or inactivate viral contaminants during biopharmaceutical manufacturing operations that need to meet safety standards and regulatory requirements. Virus filtration functions as an essential purification method that uses membrane filters to achieve complete separation of viruses from biological materials that include vaccines, monoclonal antibodies, and plasma-derived products. The market experiences growth because of the rising need for biologics, the increasing incidence of chronic and infectious diseases, and the strict drug safety regulations that exist in the UK market. Future opportunities exist through two specific advancements, which include nanofiltration technology development, biologics production expansion, and increased research and development funding. The market will experience rapid growth because pharmaceutical companies are expanding their production capacity while technological advancements continue to develop.

•  The UK government initiative focuses on strengthening the life sciences ecosystem through R&D investment, regulatory reforms, and faster market access for innovative therapies. It supports biologics manufacturing and advanced filtration technologies by improving infrastructure and innovation funding.
• The government committed up to £520 million to boost domestic manufacturing of medicines and biologics, directly supporting facilities that use virus filtration technologies in production processes.
• National Institute for Health and Care Research (NIHR) strengthened its support for clinical research and translational studies, promoting the development of safer biologics and advanced purification technologies such as virus filtration. The initiative aimed to accelerate innovation from laboratory to clinical application, improve patient safety, and enhance the UK’s capabilities in cutting-edge biopharmaceutical research and healthcare solutions.

Notable Insights: -

1. The consumables segment dominated the market in 2025 and holds the largest market share, accounting for approximately 55% during the forecast period.
2. The biological segment dominated the market in 2025 and holds the largest market share, accounting for approximately 60% during the forecast period.
3. The pharmaceutical & biotechnology companies segment dominated the market in 2025 and holds the largest market share, accounting for approximately 65% during the forecast period.
4. The compound annual growth rate of the United Kingdom Virus filtration market is 9.91%.
5. The market is likely to achieve a valuation of USD 8110.9Million by 2035.

What is the role of technology in grooming the market?

Technology plays a crucial role in shaping the United Kingdom virus filtration market by enhancing the efficiency, reliability, and scalability of filtration processes. Advanced membrane technologies, including nanofiltration and high-performance polymer filters, enable precise removal of viral contaminants while maintaining product integrity. Automation and digital monitoring systems improve process control, reduce human error, and ensure compliance with stringent regulatory standards. The adoption of single-use filtration systems has increased flexibility, minimized contamination risks, and lowered operational downtime in biopharmaceutical manufacturing. Additionally, continuous innovations in filter design and material science support higher throughput and cost-effectiveness. These technological advancements collectively drive productivity, support large-scale biologics production, and strengthen the overall competitiveness of the UK virus filtration market.

Market Drivers

The market for virus filtration in the United Kingdom operates mainly because medical facilities require more biologics, which include vaccines, monoclonal antibodies, and gene therapies. The need to produce biopharmaceuticals in a secure manner has become more urgent because of the increasing cases of both chronic and infectious diseases. The implementation of advanced filtration technologies receives a boost from the strict viral safety and product purity regulations that manufacturers must follow. The market experiences growth because of increased funding for biotechnology research, the construction of new pharmaceutical production facilities, and the industry shift towards single-use filtration technology. The UK market experiences growth because of two main drivers, which are technological improvements in nanofiltration and membrane efficiency, and the rising trend of contract manufacturing organization outsourcing.

Restrain

The United Kingdom virus filtration market faces restraints due to the high costs of advanced filtration systems and stringent regulatory requirements that increase compliance burden. Limited scalability for certain filtration technologies and risk of filter fouling also hinder efficiency. Additionally, smaller manufacturers often struggle with capital investment and validation complexities, slowing widespread adoption.

Study on the Supply, Demand, Distribution, and Market Environment of the United Kingdom Virus Filtration Market

The United Kingdom Virus Filtration Market demonstrates a well-structured supply, demand, distribution, and market environment driven by its strong life sciences sector. On the supply side, global manufacturers such as Merck KGaA and Danaher Corporation provide advanced filtration membranes, consumables, and systems through established distribution networks, ensuring consistent availability. Demand is primarily generated by biopharmaceutical companies, contract research organizations, and medical device manufacturers due to the increasing production of biologics and strict viral safety requirements. In terms of distribution, companies rely on direct sales, partnerships, and specialized distributors to reach pharmaceutical manufacturers and research institutes efficiently. The market environment is highly regulated, innovation-driven, and research-oriented, supported by the UK’s strong R&D ecosystem and compliance standards. Growing investments in biologics, rising disease prevalence, and increasing outsourcing of filtration services continue to strengthen market expansion and operational dynamics.

Price Analysis and Consumer Behaviour Analysis

Price analysis in the United Kingdom virus filtration market indicates that costs are largely influenced by membrane material quality, filter capacity, and regulatory compliance standards. High-performance nanofiltration systems and single-use technologies typically command premium pricing due to their efficiency and reliability. Bulk purchasing by large biopharmaceutical firms helps reduce per-unit costs, while smaller manufacturers often face higher expenses. From a consumer behavior perspective, pharmaceutical and biotechnology companies prioritize product quality, validation support, and regulatory approval over price sensitivity. Buyers increasingly prefer single-use systems for flexibility and contamination control. Additionally, growing biologics production and emphasis on safety have led to long-term supplier partnerships, with customers favoring trusted brands that offer consistent performance, technical support, and compliance with stringent UK and EU regulatory frameworks.

Market Segmentation

The United Kingdom Virus Filtration Market Share is classified into type, source, and end user  

• The consumables segment dominated the market in 2025 and holds the largest market share, accounting for approximately 55% during the forecast period.

Based on the product type, the virus filtration market is divided into consumables, filtration systems, and services. Among these, the consumables segment dominated the market in 2025 and holds the largest market share, accounting for approximately 55% during the forecast period. The consumables segment is driven by filters, membranes, and cartridges that require frequent replacement in biopharmaceutical processes. Their recurring usage ensures consistent demand compared to one-time system purchases. Increasing biologics production and strict regulatory requirements further drive continuous consumption, making this segment the largest contributor to overall market revenue.

• The biological segment dominated the market in 2025 and holds the largest market share, accounting for approximately 60% during the forecast period.

Based on the application, the virus filtration market is divided into biological, medical devices, water purification, and air purification. Among these, the biological segment dominated the market in 2025 and holds the largest market share, accounting for approximately 60% during the forecast period. The biological segment in the U.K. is attributed to the growing production of vaccines, monoclonal antibodies, and gene therapies. Virus filtration is essential for ensuring viral safety in biologics manufacturing. Rising disease prevalence and strong investment in biopharmaceutical R&D in the UK significantly boost demand, making biological applications the leading segment.

• The pharmaceutical & biotechnology companies segment dominated the market in 2025 and holds the largest market share, accounting for approximately 65% during the forecast period.

Based on the end user, the virus filtration market is divided into pharmaceutical & biotechnology companies, contract research organizations (CROs), and research institutes. Among these, the pharmaceutical & biotechnology companies segment dominated the market in 2025 and holds the largest market share, accounting for approximately 65% during the forecast period. The pharmaceutical & biotechnology companies segment in the U.K. is driven by their extensive use of virus filtration in drug development and manufacturing. These companies require high-quality filtration systems to meet stringent regulatory standards. Increasing biologics pipelines and large-scale production capacities further strengthen their dominance in the market.

Recent Development

• In November 2024, Oxford Nanopore Technologies entered a strategic partnership with Genomics England, UK Biobank, and NHS England to advance genomics-driven healthcare innovation. The collaboration focused on accelerating translational research, improving disease detection, and strengthening pandemic surveillance capabilities across the UK healthcare system.
•  In October 2024, Asahi Kasei Medical launched the Planova FG1, a next-generation high-flux virus removal filter designed for biotherapeutics manufacturing. The product enhanced filtration speed and viral safety, supporting efficient biologics production. This development is relevant to the United Kingdom virus filtration market, reflecting global innovation trends adopted by UK biopharmaceutical manufacturers.
• In June 2021, Journeo (through its subsidiary 21st Century Fleet Systems) partnered with AirLabs to distribute the AirBubbl, an advanced air filtration device across UK public transport networks. The system, capable of removing over 99% of airborne viruses, enhanced passenger safety, supporting the United Kingdom virus filtration market growth.

Competitive Analysis

The report offers the appropriate analysis of the key organisations/companies involved within the United Kingdom Virus Filtration Market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

Top Key Companies in the United Kingdom Virus Filtration Market

• Merck KGaA
• Danaher Corporation
• Sartorius AG
• Thermo Fisher Scientific Inc.
• Asahi Kasei Medical Co., Ltd.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the United Kingdom, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the United Kingdom virus filtration market based on the below-mentioned segments

United Kingdom Virus Filtration Market, By Product Type

• Consumables
• Filtration Systems
• Services

United Kingdom Virus Filtration Market, By Application

• Biological
• Medical Devices
• Water Purification
• Air Purification

United Kingdom Virus Filtration Market, By End User

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)
• Research Institutes

Frequently Asked Questions (FAQ)

Q. How is the rise of contract manufacturing organizations (CMOs) influencing the UK virus filtration market?

A. The growing presence of CMOs in the UK is significantly boosting demand for virus filtration technologies. These organizations handle outsourced biologics production, requiring high-quality filtration systems to meet regulatory standards. Their expansion increases the adoption of single-use filtration solutions and drives consistent demand for consumables and advanced filtration infrastructure.

Q. What role does regulatory compliance play in shaping product innovation in the UK virus filtration market?

A. Regulatory compliance plays a critical role in driving innovation, as companies must meet strict standards set by authorities like the Medicines and Healthcare Products Regulatory Agency. This encourages the development of advanced filtration membranes, validated systems, and traceable processes that ensure viral safety, product purity, and adherence to Good Manufacturing Practices (GMP).

Q. How is the adoption of single-use technologies impacting operational efficiency in virus filtration?

A. Single-use technologies are transforming operational efficiency by reducing cleaning requirements, minimizing cross-contamination risks, and lowering downtime. These systems offer flexibility in production and are particularly beneficial for small-batch biologics manufacturing, enabling faster turnaround times and cost-effective scalability for pharmaceutical companies.

Q. What opportunities exist for innovation in virus filtration materials in the UK market?

A. Significant opportunities lie in developing advanced materials such as nanofiber membranes and high-performance polymers. These innovations improve filtration efficiency, increase throughput, and reduce fouling risks. Continuous research in material science is expected to enhance durability and cost-effectiveness, supporting next-generation biologics and gene therapy manufacturing in the UK.